Clene's CNM-Au8 Shows Statistically Significant Difference In Plasma Neurofilament Light Levels In The HEALEY ALS Platform Trial
Portfolio Pulse from Benzinga Newsdesk
Clene's CNM-Au8, a gold nanocrystal suspension, showed a statistically significant difference in plasma neurofilament light levels in the HEALEY ALS Platform Trial, indicating potential efficacy in treating ALS.
June 15, 2023 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clene's CNM-Au8 showed promising results in the HEALEY ALS Platform Trial, indicating potential efficacy in treating ALS, which may positively impact the company's stock.
The positive results from the HEALEY ALS Platform Trial for Clene's CNM-Au8 indicate potential efficacy in treating ALS. This may lead to increased investor interest and demand for the company's stock, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100